VA Pharmaceuticals (Pvt) Ltd company is conducting negotiations in order to obtain the right to manufacture a generic drug Keytruda

The pharmaceutical company AVA Pharmaceuticals (Pvt) Ltd announced the start of negotiation with the American company Merck & Co in order to obtain the right to develop and manufacture a generic drug Keytruda.

This original drug is a targeted therapy drug. Keytruda works with the innate immune system and boosts the body’s natural defenses to fight the tumor. The drug used in the treatment of unresectable or metastatic melanoma, classical lymphoma, squamous cell cancer, urothelial cancer and other types of tumors, which may be resistant to standard treatment options.

Keytruda is given intravenously two or three times a week. The duration of treatment is determined individually.

Nowadays, this preparation is regarded as the most promising avenues for cancer treatment. Results of clinical studies show that Keytruda enhances the survival rate in 62%-69% of oncological patients. However, the cost of one package of the original drug varies from 4000 to 5000 dollars. One course of treatment consists of at least eight packages of medicines, and as a result, the overall cost of treatment is simply unaffordable to many oncological patients.

The development of the generic drug and its subsequent release will be a really great salvation for millions of patients. They will be able to receive a high-quality, efficient and safe treatment at affordable prices.